Noninvasive detection of soft tissue sarcoma using volatile organic compounds in exhaled breath: a pilot study.
Ibtissam AcemVeroniek M van PraagCassidy Qb MostertRobert J P van der WalRalph Ml NeijenhuisCornelis VerhoefDirk J van GrünhagenMichiel Adreanus van de SandePublished in: Future oncology (London, England) (2023)
Aim: The aim of this pilot study was to assess whether an electronic nose can detect patients with soft tissue sarcoma (STS) based on volatile organic compound profiles in exhaled breath. Patients & methods: In this cross-sectional pilot study, patients with primary STS and healthy controls, matched on sex and age, were included for breath analysis. Machine learning techniques were used to develop the best-fitting model. Results: Fifty-nine breath samples were collected (29 STS and 30 control) from March 2018 to March 2022. The final model yielded a c-statistic of 0.85 with a sensitivity of 83% and specificity of 60%. Conclusion: This study suggests that exhaled volatile organic compound analysis could serve as a noninvasive diagnostic biomarker for the detection of STS with a good performance.